Current Report Filing (8-k)
March 04 2021 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported)
March 3,
2021
cbdMD, INC.
|
(Exact name of registrant as specified in its charter)
|
North Carolina
|
001-38299
|
47-3414576
|
(State or other jurisdiction of incorporation or
organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
8845 Red Oak Blvd, Charlotte, NC 28217
(Address of principal executive offices)(Zip Code)
Registrant's
telephone number, including area code: (704) 445-3060
_______________________________________
|
(Former name or former address, if changed since last
report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
common
|
YCBD
|
NYSE
American
|
8.0%
Series A Cumulative Convertible Preferred Stock
|
YCBDpA
|
NYSE
American
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company ☑
|
|
If an
emerging growth company, indicate by checkmark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ☐
Item
5.02
Departure
of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
As
previously reported, effective October 1, 2020 Mr. T. Ronan Kennedy
joined cbdMD, Inc. as its Chief Executive Officer. On March 3, 2021
our Board of Directors appointed Mr. Kennedy to also serve as our
Chief Operating Officer. Effective March 3, 2021 we entered into
Amendment No. 1 to the Executive Employment Agreement
(“Amendment No. 1”) with Mr. Kennedy to reflect this
additional role with our company. A copy of Amendment No. 1 is
filed as Exhibit 10.1 to this report and incorporated herein by
such reference.
Item
9.01
Financial
Statements and Exhibits.
|
|
|
|
Incorporated by Reference
|
|
Filed or
Furnished
Herewith
|
No.
|
|
Exhibit Description
|
|
Form
|
|
Date Filed
|
|
Number
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amendment
No. 1 to the Executive Employment Agreement dated March 3, 2021 by
and between cbdMD, Inc. and T. Ronan Kennedy
|
|
|
|
|
|
|
|
Filed
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
cbdMD,
Inc.
|
|
|
|
Date:
March 4, 2021
|
By:
|
/s/ T.
Ronan Kennedy
|
|
|
T.
Ronan Kennedy, Chief Financial Officer and Chief Operating
Officer
|
cbdMD (AMEX:YCBD)
Historical Stock Chart
From Aug 2024 to Sep 2024
cbdMD (AMEX:YCBD)
Historical Stock Chart
From Sep 2023 to Sep 2024